These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16925750)

  • 61. Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome.
    Borre M
    BJU Int; 2009 Jul; 104(2):205-8. PubMed ID: 19154477
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
    Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
    Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy.
    Hisasue S; Yanase M; Shindo T; Iwaki H; Fukuta F; Nishida S; Muranaka T; Miyamoto S; Tsukamoto T; Takatsuka K
    Jpn J Clin Oncol; 2008 Feb; 38(2):129-33. PubMed ID: 18281308
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Follow-up after radical prostatectomy or radiation therapy for prostate cancer.
    Montie JE
    Urol Clin North Am; 1994 Nov; 21(4):673-6. PubMed ID: 7526513
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Salvage robotic-assisted radical prostatectomy: initial results and early report of outcomes.
    Boris RS; Bhandari A; Krane LS; Eun D; Kaul S; Peabody JO
    BJU Int; 2009 Apr; 103(7):952-6. PubMed ID: 19076132
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy.
    Schroeck FR; Sun L; Freedland SJ; Albala DM; Mouraviev V; Polascik TJ; Moul JW
    BJU Int; 2008 Jul; 102(1):28-32. PubMed ID: 18384634
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Rising Prostate Specific Antigen following treatment with curative intention].
    Jakobsen H; Pedersen KV
    Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
    Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
    Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
    Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term outcome of detectable PSA levels after radical prostatectomy.
    Ahlering TE; Skarecky DW
    Prostate Cancer Prostatic Dis; 2005; 8(2):163-6. PubMed ID: 15711604
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?
    Pfitzenmaier J; Pritsch M; Haferkamp A; Jakobi H; Fritsch F; Gilfrich C; Djakovic N; Buse S; Pahernik S; Hohenfellner M
    BJU Int; 2009 Apr; 103(7):877-82. PubMed ID: 19007372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.